Grifols, SA (ES:GRF)
BME:GRF
Want to see ES:GRF full AI Analyst Report?
GRF Stock Chart & Stats
€9.05
-€0.12(-1.30%)
At close: 4:00 PM EST
€9.05
-€0.12(-1.30%)
Day’s Range― - ―
52-Week Range€8.43 - €13.70
Previous CloseN/A
Volume312.38K
Average Volume (3M)1.09M
Market Cap
€5.53B
Enterprise Value€15.28B
Total Cash (Recent Filing)€702.00M
Total Debt (Recent Filing)€9.67B
Price to Earnings (P/E)14.8
Beta0.91
Next Earnings
Jul 23, 2026EPS Estimate
0.24Next Dividend Ex-DateN/A
Dividend Yield1.37%
Share Statistics
EPS (TTM)0.61
Shares Outstanding426,129,800
10 Day Avg. Volume1,216,950
30 Day Avg. Volume1,090,725
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.40
Price to Sales (P/S)0.98
P/FCF Ratio9.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€11.17Price Target Upside23.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.83
Revenue Forecast (FY)€7.66B
Bulls Say, Bears Say
Bulls Say
Improved Cash GenerationSustained positive operating cash flow (~€1.02B TTM) and solid free cash flow (~€0.75B TTM) provide durable capacity to fund operations, service debt and support reinvestment into manufacturing and plasma centers. This improves financial resilience across cycles.
Strong Operating MarginsOperating margin near 16% and stable gross margins in the high-30s indicate persistent operational efficiency in fractionation and manufacturing. These margins create a buffer against input cost swings and support reinvestment in capacity and R&D over the medium term.
Vertically Integrated, Recurring Revenue ModelOwning plasma collection, fractionation and commercial distribution plus diagnostic instrument footprints with recurring consumables creates durable, vertically integrated cash flows. This integration secures raw material access and recurring revenue from reagents and follow-on supplies.
Bears Say
High LeverageElevated leverage (debt/equity ~1.77 TTM) and rising total debt constrain strategic flexibility, increase interest exposure and amplify earnings volatility during revenue weakness. High leverage limits capacity to pursue large M&A or cushion prolonged downturns.
Soft Recent Revenue MomentumA slight TTM revenue decline (-1.14%) signals inconsistent top-line momentum that can pressure margin leverage over time. Given the capital-intensive model, weaker revenue trends reduce capacity utilization and make margin and cashflow targets harder to sustain.
Modest Net Profitability And ReturnsDespite improvement, net margin (~5.6%) and ROE (~7.9%) remain moderate for the sector. Modest underlying profitability limits internal funding for growth, reduces buffer against pricing or cost shocks, and makes long-term value creation more sensitive to operational execution.
Grifols News
GRF FAQ
What was Grifols, SA’s price range in the past 12 months?
Grifols, SA lowest stock price was €8.43 and its highest was €13.70 in the past 12 months.
What is Grifols, SA’s market cap?
Grifols, SA’s market cap is €5.53B.
When is Grifols, SA’s upcoming earnings report date?
Grifols, SA’s upcoming earnings report date is Jul 23, 2026 which is in 44 days.
How were Grifols, SA’s earnings last quarter?
Grifols, SA released its earnings results on May 07, 2026. The company reported €0.107 earnings per share for the quarter, missing the consensus estimate of €0.139 by -€0.032.
Is Grifols, SA overvalued?
According to Wall Street analysts Grifols, SA’s price is currently Undervalued.
Does Grifols, SA pay dividends?
Grifols, SA pays a Annually dividend of €0.15 which represents an annual dividend yield of 1.37%. See more information on Grifols, SA dividends here
What is Grifols, SA’s EPS estimate?
Grifols, SA’s EPS estimate is 0.24.
How many shares outstanding does Grifols, SA have?
Grifols, SA has 426,129,800 shares outstanding.
What happened to Grifols, SA’s price movement after its last earnings report?
Grifols, SA reported an EPS of €0.107 in its last earnings report, missing expectations of €0.139. Following the earnings report the stock price went up 0.904%.
Which hedge fund is a major shareholder of Grifols, SA?
Currently, no hedge funds are holding shares in ES:GRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Grifols Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.39%
12-Months-Change
Fundamentals
Return on Equity
7.88%
Trailing 12-Months
Asset Growth
-4.29%
Trailing 12-Months
Company Description
Grifols, SA
Grifols, S.A., a Spanish company established in 1940 and headquartered in Barcelona, specializes in the comprehensive process of acquiring, manufacturing, preparing, and distributing therapeutic products, with a primary focus on those derived from plasma. The company operates through several key divisions: Bioscience, Hospital, Diagnostic, and Bio Supplies, among others. The Bioscience division is dedicated to the research, development, production, and commercialization of plasma-derived medicines and other cutting-edge solutions. These are designed to treat individuals suffering from chronic, rare, widespread, and life-threatening medical conditions, with its product portfolio including immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division supplies a range of non-biological pharmaceutical products, clinical nutrition items, intravenous (IV) therapy solutions, and various medical devices and supplies. Grifols' Diagnostic division develops and markets advanced diagnostic tools that support healthcare professionals across the entire patient care continuum, from prevention and screening to accurate diagnosis, prognosis, and ongoing disease and treatment monitoring. Finally, the Bio Supplies division provides essential biological materials for life-science research, clinical trials, and the manufacturing of both pharmaceutical and diagnostic goods. Collectively, Grifols' offerings enable healthcare providers to effectively diagnose and treat a broad spectrum of medical conditions, such as hemophilia, various immune deficiencies, and infectious diseases. Its diverse client base includes public and private sector organizations, wholesalers, distributors, group purchasing organizations (GPOs), blood banks, hospitals, care institutions, and national health systems. Grifols also maintains a technology collaboration agreement with Mondragon.
GRF Stock 12 Month Forecast
Average Price Target
€11.17
▲(23.39% Upside)
Technical Analysis
Almirall
―
Faes Farma
―
LABORATORIO REIG JOFRE
―
Laboratorios Farmaceuticos Rovi
―
Pharma Mar SA
―
Options Prices
Currently, No data available
---